Drug Design, Development and Therapy
2026
Jie Yang, Qiqi Yan, Ting Zhang et al.
Esketamine is increasingly being applied for preventing postpartum depression (PPD). However, clinical protocols for this application are inconsistent, particularly concerning the route of administration. The aim was to determine whether esketamine bolus administration differed from continuous infusion in terms of preventing PPD. A total of 503 subjects without prenatal depression undergoing...
Drug Design, Development and Therapy
2026
Fan Bu, Lan Qin, Zhengchi Lou et al.
Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability...
Drug Design, Development and Therapy
2026
Yanhong Li, Kuangyu Zhao, Peipei Cao et al.
Surgical stress can lead to postoperative anxiety and depression, especially in adolescents. These complications reduce quality of life and increase medical burdens, but perioperative psychological interventions for adolescents are limited, and related mechanisms remain unclear. Esketamine (S-ketamine), an N-methyl-D-aspartate receptor (NMDAR) antagonist, has analgesic, sedative,...
Drug Design, Development and Therapy
2025
Xingyu Geng, Yutian Pu, Ziwei Hu et al.
7 citations
Postoperative sleep disturbance(POSD) is a problem in breast cancer patients after surgery. Little is known about the differences in the treatment of POSD with esketamine combined with dexmedetomidine under the same circumstances. We investigated the effects of intraoperative esketamine combined with intravenous dexmedetomidine on the incidence of POSD and postoperative sleep architecture. A...
Drug Design, Development and Therapy
2025
Xiao Huang, Xueyang Li, Yuan Sun et al.
5 citations
Propofol and sufentanil are the most commonly used anesthetics during bronchoscopy. Esketamine is an s-enantiomer of ketamine racemate and has both sedative and analgesic effects, it does not inhibit respiration and maintains hemodynamic stability. We aimed to compare the intraoperative hypoxemia risk of esketamine/propofol with sufentanil/propofol for patients in bronchoscopy. This study was...
Drug Design, Development and Therapy
2025
Xiaoshan Li, Shengchao Li, Chanyan Xu et al.
3 citations
This research aimed to quantify the impact of low dose of esketamine on BIS and validate the feasibility of closed-loop TCI system based on the new BIS baseline with low dose of esketamine. This study consisted of two phases. The first phase was to quantify the impact of a low dose of esketamine (0.2mg kg-1 bolus, 5μg kg-1 min-1 infusion for 30min) on BIS and establish a new BIS baseline for...
Drug Design, Development and Therapy
2025
Yuting Li, Hongxiang Li, Feng Zhang et al.
3 citations
Analgesics and sedatives may affect the hemodynamics of patients with septic shock and produce adverse reactions. The purpose of this study is to compare the hemodynamic effects and prognosis of esketamine and remifentanil in combination with propofol in patients with septic shock receiving invasive mechanical ventilation. In this single-center, prospective, randomized, controlled pilot study,...
Drug Design, Development and Therapy
2025
Jiajia Li, Gaili Jia, Ruixian Wang et al.
To investigate the efficacy of intranasal esketamine in reducing the incidence of emergence agitation (EA) in pediatric patients undergoing adenotonsillectomy and to determine the optimal dose of esketamine. A total of 204 children aged 3-6 years scheduled for adenotonsillectomy were randomly assigned to three groups. All participants received a standardized anesthetic induction protocol....
Drug Design, Development and Therapy
2025
Yingchao Guan, Haochen Wang, Xiaojing Cong et al.
We explored whether esketamine anesthesia during first-trimester surgical abortion can reduce intraoperative hemodynamic fluctuations and improve patients' respiratory function. A total of 197 patients who underwent a first-trimester surgical abortion were included in the analysis. Patients were randomly assigned to either the esketamine anesthesia group (group E, n=98) or sufentanil anesthesia...
Drug Design, Development and Therapy
2024
Chao-Bang Ma, Cheng-Yang Zhang, Cai-Li Gou et al.
27 citations
Postoperative delirium (POD) is a prevalent and severe complication in elderly patients undergoing major surgery, associated with increased morbidity and mortality. This randomized controlled trial aimed to investigate the effects of low-dose esketamine on the incidence of POD in elderly patients underwent total hip or knee arthroplasty. Two hundred and sixty elderly participants were randomly...
Drug Design, Development and Therapy
2024
Sarah A Norring, Michael G Spigarelli
22 citations
Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of...
Drug Design, Development and Therapy
2024
Bo-Ran Deng, Yang Zhang, Zi-Feng Xie et al.
18 citations
The debate continues over the differential impact of remimazolam vs propofol on hemodynamic stability. This study aims to elucidate the effects of a combination of remimazolam and esketamine vs propofol and esketamine on hemodynamic parameters in elderly patients undergoing painless colonoscopies. We conducted a randomized controlled trial involving 754 patients, divided equally between two...
Drug Design, Development and Therapy
2024
Mengcao Weng, Dongdong Wang, Jia Zhong et al.
17 citations
This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile. This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamine + propofol) or group...
Drug Design, Development and Therapy
2024
Yanling Liao, Siyu Xie, Yifen Zhuo et al.
14 citations
Emergence delirium and postoperative negative behavioral changes (PNBC) are common complications in pediatric anesthesia. This study evaluated whether intranasal premedication combining dexmedetomidine and esketamine more effectively reduces these complications compared to either drug alone in children undergoing tonsillectomy and/or adenoidectomy with sevoflurane anesthesia. This randomized,...
Drug Design, Development and Therapy
2024
Yanping Shen, Lijun Yin, Binnan Hu et al.
7 citations
Propofol injection pain (PIP) is a frequent adverse effect during anesthesia induction, impacting patient comfort and satisfaction. Esketamine has been shown to alleviate PIP, but the optimal dose, especially in relation to preoperative anxiety levels, remains unclear. Preoperative anxiety may heighten pain perception and influence analgesic requirements. A randomized, double-blind, controlled...
Drug Design, Development and Therapy
2024
Liangliang Gao, Xinyu Lu, Aiping Tan et al.
3 citations
Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate. One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two...
Drug Design, Development and Therapy
August 1, 2019
Alexandrine Corriger, G. Pickering
197 citations
Abstract Depression is the third leading cause of disability in the world. Depressive symptoms may be reduced within several weeks after the start of conventional antidepressants, but treatment resistance concerns one-third of patients who fail to achieve recovery. Over the last 20 years, ketamine, an antagonist of the N-methyl-D-aspartate receptor, has been described to have antidepressant...